Respiratory Tract Diseases  >>  Flublok (influenza vaccine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
NCT00395174: Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Completed
3
870
US
Influenza Vaccination, FluBlok, Fluzone, rHA, rHA0, recombinant hemagglutinin, TIV
Protein Sciences Corporation
Influenza
05/07
05/07
NCT00539864: Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

Completed
3
602
US
FluBlok Influenza Vaccination, FluBlok, rHA, rHA0, recombinant hemagglutinin, TIV (Fluzone) Influenza Vaccination, Fluzone, TIV
Protein Sciences Corporation
Influenza
04/08
04/08
NCT01767896: Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Completed
3
1020
Japan
ASP7374, approved egg-derived TIV, Influenza HA vaccine "SEIKEN"
UMN Pharma Inc.
Influenza
03/13
03/13
NCT01825200: Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Completed
3
2640
US
Flublok, Afluria
Protein Sciences Corporation
Influenza
05/13
05/13
NCT01961947: Study of ASP7374, Cell-culture-derived Influenza Vaccine

Completed
3
900
Japan
ASP7374, approved egg-derived TIV, Influenza HA vaccine "SEIKEN"
UMN Pharma Inc.
Influenza, Vaccine
11/13
11/13
NCT00328107: Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Completed
2/3
459
US
Influenza Vaccine, recombinant Hemagglutinin, FluBlok, rHA, rHA0, recombinant hemagglutinin
Protein Sciences Corporation
Influenza
08/05
08/05

Download Options